19th DIA Japan Annual Meeting 2022

New “Quest for the future”~Moving Creativity and Innovation Forward in “New Normal”~

LS03 Considering Benefit-Risk Assessment in New Drug Applications

Session Chair(s)

Mamoru Narukawa, PhD, RPh

• Professor, Department of Clinical Medicine (Pharmaceutical Medicine)
• Graduate School of Pharmaceutical Sciences, Kitasato University, Japan

Speaker(s)

Katsuhiko Ichimaru

• Review Director, Office of New Drug IV
• Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Yuko Asahara

• Global Drug Development Div, Regulatory Writing and Submissions, Head
• Novartis Pharma K.K., Japan

Mamoru Narukawa, PhD, RPh

• Professor, Department of Clinical Medicine (Pharmaceutical Medicine)
• Graduate School of Pharmaceutical Sciences, Kitasato University, Japan